

UNCLASSIFIED

AD 264 698

*Reproduced
by the*

ARMED SERVICES TECHNICAL INFORMATION AGENCY
ARLINGTON HALL STATION
ARLINGTON 12, VIRGINIA



UNCLASSIFIED

Reproduced From
Best Available Copy

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

397-300

1

EC

244200
1110
76

HAZLETON LABORATORIES
INCORPORATED

Falls Church, Virginia

October 10, 1961

PROGRESS REPORT
No. 16

Contract No. DA 18-108-405-CML-826

XEROX
67-6-6

1110
76

ASTIA
OCT 19 1961
TIPQ8

I. Basic Screening Program

A. Compounds Screened - September

Compound Symbol	Dose Range		CAR*	SPE*	VDT*
	Cat	Dog			
CS 1022			x		
CS 3861			x		x
CS 4297					x (7)
CS 5348		x		x	
CS 5349		x		x	
CS 6316	x	x			
CS 10121		x		x	
CS 10523		x		x	
CS 11207			x	x	
CS 11270	x	x		x	
CS 11469	x	x		x	
CS 11867	x	x		x	
CS 12233	x	x		x	
CS 12243			x		
CS 12805			x	x	
CS 12807			x	x	
CS 12810			x	x	
CS 12833			x		
CS 12933			x	x	
CS 13025	x	x			
CS 13053				x	
CS 13389			x		
CS 13390			x		
CS 13459	x	x			
CS 13466			x (2)		x (2)
CS 13759		x		x	
CS 14116	x	x			
CS 14121	x	x			
CS 14633			x		
(powder)					
CS 14633			x		
(liquid)					
CS 16567			x		
CS 16576					x
CS 19628			x	x	
CS 19980	x	x	x	x	
CS 19987			x		
CS 20000		x		x	
CS 23654	x	x			
EA 1649	x				
EA 1650	x	x			
EA 2277					x
atropine sulfate					x (2)
chlorpromazine					
hydrochloride					x (2)
d-lysergic acid					
diethylamide			x		x
Total	13	18	20	18	17

* CAR = Conditioned Avoidance Response SPE = Sustained
Physical Exercise VDT = Visual Discrimination Test

B. Compounds To Be Screened .. October

Compound Symbol	Dose Range		CAR*	SPE*	VDT**
	Cat	Dog			
CS 5348			x		
CS 5349			x		
CS 6316			x	x	
CS 9314	x	x	x	x	
CS 10121			x		
CS 10523			x		
CS 11270			x		
CS 11469			x		
CS 11867			x		
CS 11925	x	x	x	x	
CS 11926	x	x	x	x	
CS 12233			x		
CS 13025			x	x	
CS 13053			x		
CS 13459			x	x	
CS 13759			x		
CS 14116			x	x	
CS 14121			x	x	
CS 20000			x		
CS 23654			x	x	
EA 1649		x	x	x	
EA 1650			x	x	
EA 2172	x	x	x	x	
EA 2216	x	x		x	
EA 2217	x	x		x	
EA 2218	x	x		x	
EA 2227	x	x		x	
EA 2237	x	x		x	
EA 2238	x	x			
EA 2264	x	x			
EA 2265	x	x			
EA 2362	x	x			
EA 2363	x	x			
EA 2364	x	x			
EA 2389	x	x			
EA 2391	x				
92540	x	x	x	x	
92545	x	x	x	x	
92574	x	x		x	
92686	x	x		x	
92696	x	x		x	
92864	x	x		x	
92877	x	x		x	
92878	x	x		x	
Total	25	25	25	25	

* CAR = Conditioned Avoidance Response SPE = Sustained Physical Exercise VDT = Visual Discrimination Test

** None proposed due to the control testing of all VDT monkeys with saline for obtaining negative control data, in order to assist in validating the grading criteria.

II. Skin Penetration Testing Program

A. Completed

Skin screening of 60 compounds were completed and the results are submitted.

B. Projected

Skin penetration testing of 35 additional compounds which are presently available.

III. Preclinical Pharmacology Program

A. Completed and Submitted in this Report Group

1. Preclinical pharmacology studies of EA 1476 in rats and dogs.
2. Dose regression studies of EA 1476 in dogs and monkeys.

B. In Progress

None

IV. Additional Effort Requirements

A. Completed and Submitted in this Report Group

1. Dose regression and VDT studies of CS 4640, CS 12614, and CS 12615 in monkeys.
2. Antagonism studies between CS 4297 and CS 12602 in the VDT in monkeys.
3. A comparative study between CS 4297 and CS 22773 in the VDT in monkeys.

B. In Progress

1. A comparative study of atropine with scopolamine in the VDT in monkeys.
2. Final comprehensive reports on compounds which were found to be of interest between April 1 and September 30, 1961.

C. Projected

1. Continuation of a tolerance study on EA 2277 in the CAR test in dogs.
2. Further primary screening of compounds which were found to be of possible interest.

UNCLASSIFIED

UNCLASSIFIED